ARA-290 Peptide: Benefits, Side Effects, and Reported Dosage Ranges

ARA-290 peptide benefits cluster almost entirely around nerve repair, the side effects logged in human trials were mild enough that investigators struggled to separate them from placebo, and dosage in those same trials converged on one number rather than a range. That is an unusual position for a research peptide, and it is worth understanding why before you read anything else about it.

What ARA-290 Actually Is

Two jobs sit inside one hormone. Erythropoietin drives red cell production in bone marrow, and it separately keeps damaged tissue alive. Bundled that way, EPO was useless as a repair drug, because pushing someone's hematocrit up to treat their neuropathy trades a nerve problem for a clotting problem.

The work by Michael Brines and Anthony Cerami established that the two run through different receptors and different parts of the EPO molecule. The tissue protection signal lives on a region called the helix B surface. Copy that region as a short synthetic peptide and you get the repair signal on its own. That copy is ARA-290, also written as cibinetide, and in the older literature as pHBSP, short for pyroglutamate helix B surface peptide.

Chemistry worth checking against your vendor's listing:

• Length: 11 amino acids
• Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
• Molecular weight: approximately 1,257 Da
• Form: white lyophilized powder, commonly in 16 mg or 32 mg vials
• Developer: Araim Pharmaceuticals

One practical warning. Sequence listings for ARA-290 across supplier sites and peptide databases are not consistent, and some catalogs publish an entirely different string of residues under the same name. A vendor that cannot state the sequence correctly on its own product page is not one whose analytical documents mean much.

Mechanism. Classical EPO signaling works through a homodimer of two EPO receptor subunits on red cell precursors. ARA-290 does not bind that. It binds the innate repair receptor, or IRR, a mixed complex of one EPO receptor subunit and the common beta receptor, CD131.

The IRR is conditional, and that conditionality is the whole design. Expression of the complex climbs under hypoxia, inflammation, metabolic strain, and nerve damage, and stays low where none of those apply. The result is a compound whose distribution of effect is set by the tissue rather than by the dose: an uninjured organ simply presents no docking site for it.

Reported downstream consequences run in roughly this sequence. Local macrophages shift away from an inflammatory posture toward a repair one. Cytokine output at the injury site falls, TNF-alpha and the interleukin-1 and interleukin-6 arms included. Survival signaling through PI3K/Akt is engaged in cells that would otherwise commit to apoptosis. Schwann cells persist and axons regrow. New capillary formation gets a modest push.

None of that requires the peptide to hang around. Plasma clearance is fast, with renal elimination and a reported half life on the order of minutes to a couple of hours depending on the model. Effects outlast the molecule because receptor engagement triggers gene expression changes that continue after clearance, which is the standard explanation for why a 28 day course produced findings still measurable weeks later.

ARA-290 is not approved for human use in any market. Everything below describes what has been reported in research settings, not a protocol for anyone to follow.

ARA-290 Benefits

The evidence base here is narrow, unusually deep in one place, and thin everywhere else. Grading it properly means separating the human work from the animal work, because the gap between them is wide.

Diabetic peripheral neuropathy (human trial data). The strongest column by some distance. Placebo controlled Phase 2 work in type 2 diabetes patients with neuropathic symptoms ran a 28 day course and tracked small nerve fiber density directly, using objective structural methods rather than a symptom questionnaire. Fiber density improved relative to placebo. That distinction carries most of the weight here: a count of nerve fibers is much harder to move by expectation than a patient rating their own pain, which is exactly why neuropathy trials that rest on questionnaires alone convince so few people. Pain and sensory measures improved alongside the structural finding.

Sarcoidosis associated small fiber neuropathy (human trial data). This neuropathy responds poorly to conventional analgesia and the population has few options. Phase 2 work reported gains in nerve fiber density, lower pain scores, and improvement in fatigue, frequently the most disabling symptom, with circulating inflammatory markers moving in the expected direction. This is the indication behind the Orphan Drug designation.

Beta cell protection and metabolic effects (mostly preclinical). Pancreatic beta cells express the IRR when stressed by high glucose or inflammation, and animal work shows reduced beta cell death under those conditions. The human signal is limited to glycemic improvements seen inside neuropathy trials, which those trials were not designed to test. A hypothesis, not a finding.

Broader anti-inflammatory and organ protection (animal data only). Rodent models cover joint inflammation, sepsis survival, kidney injury, and cardiac ischemia reperfusion, and results are consistently positive. They are also rodent results, and preclinical anti-inflammatory data has a poor historical record of translating. ARA-290 at least has human evidence somewhere in its file, unlike KPV, but not in these applications.

Mood and neuroinflammation (early animal work). Mice under chronic stress showed reduced depression like behavior and lower hippocampal inflammatory markers, which connects to the inflammatory hypothesis of treatment resistant depression. No human trial supports this use. It is a research direction, not a benefit.

What ARA-290 has never demonstrated, and was specifically engineered not to do, is raise red blood cell mass. If a seller markets it for endurance or oxygen carrying capacity, they have misunderstood the entire point of the molecule.

ARA-290 Side Effects

The published safety picture is genuinely mild, and it is worth being precise about why rather than repeating that it is well tolerated.

Documented in human trials:

• Injection site reactions, mild and short lived, the most commonly reported effect
• Mild fatigue, generally in the first days of a course
• Headache, uncommon, usually early
• Gastrointestinal discomfort, rare
• No change in hemoglobin, hematocrit, or red cell count, confirmed by direct measurement
• No thromboembolic or hypertensive signals, in contrast to EPO
• No neutralizing antibody response reported

The absence of hematological effects is the most important safety fact here, and it is a mechanistic consequence rather than a lucky result. Because ARA-290 does not engage the classical EPO receptor homodimer, the pathway that raises blood viscosity is never activated, which removes the stroke and clotting concerns that make chronic EPO use untenable.

Where the data is thin, and it is thinner than the safety summaries suggest:

Trial exposure was measured in weeks, not years, and there is no long term human data for the repeated annual cycling that describes actual use outside trials. No human dose escalation toxicity study has been published, so the upper bound of tolerability is unknown rather than established as high.

A theoretical concern also gets glossed over. CD131 is expressed on some tumor cell types, and IRR signaling is an anti-apoptotic survival pathway. Nobody has shown that ARA-290 promotes tumor growth, and nobody has ruled it out. Pregnancy, breastfeeding, and pediatric use have no safety data at all. Combining ARA-290 with erythropoiesis stimulating agents such as EPO or darbepoetin has not been studied.

ARA-290 Dosage Chart

Every figure below comes from published trial protocols or from documented reports of research use. None of it is a recommendation, and no human dosing standard exists for this compound because no regulator has approved it.

Three things about this table deserve emphasis.

First, the figures above 4 mg have no trial basis at all. They circulate through community reports, and because no human dose escalation toxicity study has been published, the safety of that upper band is unknown rather than reassuring. Unknown is not a synonym for fine.

Second, the 4 mg figure has been repeated so widely that it now reads like a consensus. It is not one. It is a single protocol carried forward from one development program, never the output of a dose ranging study that put 2 mg, 4 mg, and 8 mg side by side and compared what each one achieved. The dose is conventional, not optimized.

Third, the cycling pattern in the last row has no clinical origin whatsoever. Trials ran a single 28 day course and stopped. Repeated cycles separated by washout periods are a practice imported from how other research peptides get used, not something any published ARA-290 protocol tested.

Reconstitution and Storage

ARA-290 ships as a lyophilized powder and has to be reconstituted before use in any injectable research application.

Bacteriostatic water is the standard diluent. Add it slowly against the vial wall rather than onto the powder cake, and swirl rather than shake. Two milliliters into a 16 mg vial lands at 8 mg per mL, which puts a 4 mg quantity at half a milliliter, or the 50 unit mark if you are measuring on a U-100 insulin syringe. Doubling both figures, 4 mL into a 32 mg vial, holds that same concentration and keeps the arithmetic identical.

Supplier storage guidance is consistent on the essentials. Keep sealed lyophilized vials frozen near minus 20 degrees Celsius for long term storage, or refrigerated at 2 to 8 degrees Celsius for shorter periods, and refrigerate once reconstituted. Published shelf life estimates for the reconstituted solution vary widely, from about one week to several weeks, which is a reason to prepare conservatively rather than trust the longest figure you find. Protect from light, never freeze a reconstituted vial, and discard anything cloudy or discolored.

Stacking

Combination data for ARA-290 is close to nonexistent, and no published trial has run it alongside another peptide. What follows is mechanistic reasoning, a weaker basis than it usually gets credit for.

The commonly discussed pairing is with BPC-157, on the logic that the two work through non overlapping pathways: IRR mediated protection of stressed nerve tissue on one side, angiogenic and growth factor driven soft tissue repair on the other. Coherent argument. Untested.

Where inflammation rather than structural injury is the focus, KPV, which acts inside the cell on NF-kB signaling, and LL-37, which works largely through antimicrobial and immune modulating activity, make more sense as comparisons than as additions. Running several inflammation targeting peptides at once makes it impossible to attribute any observed effect to any one of them.

One pairing is worth ruling out flatly: ARA-290 alongside any erythropoiesis stimulating agent. The peptide leaves hematocrit alone by itself, but layering it onto something built to raise red cell mass produces a combined exposure that no published work has examined, and the receptor overlap between the two makes that a genuinely open question rather than a formality.

How to Verify What You Buy

ARA-290 is expensive to synthesize correctly and the market for it is small, exactly the profile that attracts underdosed and mislabeled product. Ask for a batch specific third party certificate of analysis carrying both HPLC purity and mass spectrometry identity, and check that the reported mass lands near 1,257 Da. Our ARA-290 buying guide covers which suppliers publish batch level documents and which reuse one file across lots.

Frequently Asked Questions

What does ARA-290 peptide do?

It activates the innate repair receptor on injured or inflamed tissue, which triggers anti-inflammatory signaling, cell survival pathways, and nerve repair processes. In human trials the measurable result was regrowth of small nerve fibers in patients with diabetic and sarcoidosis related neuropathy. It does not stimulate red blood cell production, despite being derived from erythropoietin.

Is ARA-290 safe?

In published Phase 2 trials adverse events were mild and comparable to placebo, with no effect on blood counts and no cardiovascular signals. That is a good short term record, but not an established safety profile: exposure lasted weeks, no human dose escalation toxicity study exists, and long term repeated use has never been studied. It is not an approved drug.

How much ARA-290 was used in studies?

Both major Phase 2 programs settled on 4 mg once daily across a 28 day course. Reported use outside trials tracks that same figure, sometimes preceded by a smaller introductory amount and occasionally pushed to 8 mg, though nothing above 4 mg has trial support behind it. Treat all of these as reported ranges rather than instructions, and note that the repeated cycling described in community protocols was never part of any studied schedule.

Is ARA-290 legal?

Scheduling is not the issue with cibinetide, since it sits outside controlled substance frameworks entirely. Approval is the issue. No regulator, the FDA included, has cleared it for any indication, which means selling or marketing it for human use is not lawful anywhere. Distribution runs on laboratory research terms instead, and what an individual may purchase or hold varies considerably from one country to the next.